

Amendments to the Claims

1. (Currently Amended) A method for treating a cancer patient ~~having a disease associated with undesirable or uncontrolled cell proliferation, the method~~ comprising:

administering to the patient a 20(S)-camptothecin for a period of time during which a ~~pyrimidine base analog~~ 5-fluorouracil is not being administered to the patient; and

administering a ~~pyrimidine base analog~~ 5-fluorouracil to the patient, wherein the period of time during which 5-fluorouracil is not being administered to the patient is at least 1 day.

2. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

3. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

4. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

5. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

6. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

7. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 1 and 90 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

8. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

9. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
10. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
11. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 5 and 90 days before ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
12. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 1 day after ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
13. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 2 days after ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
14. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 3 days after ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
15. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 4 days after ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
16. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered at least 5 days after ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
17. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 1 and 90 days before or after ~~the pyrimidine base analog~~ 5-fluorouracil is administered and is also administered within 1 day of when ~~the pyrimidine base analog~~ 5-fluorouracil is administered.
18. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 2 and 90 days before or after ~~the pyrimidine base analog~~ 5-fluorouracil is administered and is also administered within 2 days of when ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

19. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 3 and 90 days before or after ~~the pyrimidine base analog~~ 5-fluorouracil is administered and is also administered within 3 days of when ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

20. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin is administered between 4 and 90 days before or after ~~the pyrimidine base analog~~ 5-fluorouracil is administered and is also administered within 4 days of when ~~the pyrimidine base analog~~ 5-fluorouracil is administered.

21. (Currently Amended) A method according to claim 1 wherein the patient has pancreatic cancer ~~wherein the pyrimidine base analog is a fluorinated analog of a pyrimidine base.~~

22. (Canceled)

23. (Original) A method according to claim 1 wherein the 20(S)-camptothecin is 9-nitro-20(S)-camptothecin.

24. (Canceled)

25. (Currently Amended) A method according to claim 1 wherein the patient has cancer is selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostate, and stomach cancer.

26-53. (Canceled)